[{"id":"2487ddb2-7738-4021-b64c-94036379e85b","acronym":"CHAMP","url":"https://clinicaltrials.gov/study/NCT04709276","created_at":"2021-01-19T20:52:08.240Z","updated_at":"2025-02-25T14:29:51.192Z","phase":"Phase 2","brief_title":"A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer","source_id_and_acronym":"NCT04709276 - CHAMP","lead_sponsor":"Andrew J. Armstrong, MD","biomarkers":" TP53 • PTEN • RB1 • SYP","pipe":" | ","alterations":" LDH elevation","tags":["TP53 • PTEN • RB1 • SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • cabazitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 06/07/2021","start_date":" 06/07/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-14"},{"id":"ac72e48c-1524-449b-acbb-64797b142680","acronym":"","url":"https://clinicaltrials.gov/study/NCT04965597","created_at":"2021-07-16T13:53:25.569Z","updated_at":"2025-02-25T16:32:32.043Z","phase":"Phase 2","brief_title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","source_id_and_acronym":"NCT04965597","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • GATA2 • HLA-B • HLA-C","pipe":" | ","alterations":" LDH elevation","tags":["HLA-DRB1 • HLA-DQB1 • GATA2 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • fludarabine IV • busulfan • Grafapex (treosulfan) • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/19/2022","start_date":" 04/19/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-07"},{"id":"ffcc36de-86c4-4efe-bf14-26220583e249","acronym":"TOP-FLOR","url":"https://clinicaltrials.gov/study/NCT05788081","created_at":"2023-03-28T14:05:15.158Z","updated_at":"2025-02-25T14:17:47.899Z","phase":"Phase 2","brief_title":"Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.","source_id_and_acronym":"NCT05788081 - TOP-FLOR","lead_sponsor":"Olivia Newton-John Cancer Research Institute","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive • LDH elevation","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Rituxan (rituximab) • golcadomide (CC-99282)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/31/2023","start_date":" 08/31/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-06-26"},{"id":"366da270-8f09-44d6-be12-90adac16a8b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06085729","created_at":"2023-10-17T15:12:33.301Z","updated_at":"2024-07-02T16:35:16.807Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)","source_id_and_acronym":"NCT06085729","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • PTEN • RB1","pipe":" | ","alterations":" TP53 mutation • PTEN mutation • LDH elevation","tags":["TP53 • PTEN • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • PTEN mutation • LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rybrevant (amivantamab-vmjw) • Tepmetko (tepotinib) • cabazitaxel • Hepacid (pegargiminase)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/29/2024","start_date":" 02/29/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-03-01"},{"id":"365bcd51-2ab8-4615-b16d-85cc815ed781","acronym":"","url":"https://clinicaltrials.gov/study/NCT01505569","created_at":"2021-01-18T06:19:27.289Z","updated_at":"2025-02-25T14:00:01.019Z","phase":"","brief_title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","source_id_and_acronym":"NCT01505569","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" MYCN • CD34","pipe":" | ","alterations":" LDH elevation • MYCN expression","tags":["MYCN • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation • MYCN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • ifosfamide • etoposide IV • melphalan • mesna • thiotepa • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 10/20/2011","start_date":" 10/20/2011","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2024-02-26"},{"id":"eebdaec7-8bc0-4eb9-b309-c5452caff6c9","acronym":"RENOIR","url":"https://clinicaltrials.gov/study/NCT02390869","created_at":"2021-01-18T11:23:57.919Z","updated_at":"2024-07-02T16:35:37.136Z","phase":"Phase 3","brief_title":"Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients","source_id_and_acronym":"NCT02390869 - RENOIR","lead_sponsor":"Fondazione Italiana Linfomi - ETS","biomarkers":" BCL2","pipe":" | ","alterations":" LDH elevation","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 01/25/2023","primary_completion_date":" 01/25/2023","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-09-13"},{"id":"d00bd6f8-1adb-457b-b759-01497ed58d93","acronym":"","url":"https://clinicaltrials.gov/study/NCT02663232","created_at":"2021-01-18T12:58:39.783Z","updated_at":"2024-07-02T16:35:44.129Z","phase":"","brief_title":"Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma","source_id_and_acronym":"NCT02663232","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • LDH elevation • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • LDH elevation • BRAF wild-type"],"overall_status":"Completed","enrollment":" Enrollment 264","initiation":"Initiation: 06/01/2013","start_date":" 06/01/2013","primary_txt":" Primary completion: 10/01/2014","primary_completion_date":" 10/01/2014","study_txt":" Completion: 10/01/2014","study_completion_date":" 10/01/2014","last_update_posted":"2023-07-03"},{"id":"f263e4c7-8d97-4e67-989f-b832aa084e2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01873326","created_at":"2021-01-18T08:23:43.317Z","updated_at":"2024-07-02T16:35:44.198Z","phase":"Phase 2","brief_title":"Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors","source_id_and_acronym":"NCT01873326","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" AFP","pipe":" | ","alterations":" LDH elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • ifosfamide • etoposide IV • bleomycin • mesna"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 06/01/2013","start_date":" 06/01/2013","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-06-30"},{"id":"1c6b5f95-854d-4762-be43-9df4c5060a57","acronym":"","url":"https://clinicaltrials.gov/study/NCT00290511","created_at":"2021-01-18T00:59:24.844Z","updated_at":"2024-07-02T16:36:11.677Z","phase":"Phase 2","brief_title":"Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma","source_id_and_acronym":"NCT00290511","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":" | ","alterations":" LDH elevation","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • mitoxantrone • fludarabine IV • Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 06/29/2004","start_date":" 06/29/2004","primary_txt":" Primary completion: 02/12/2021","primary_completion_date":" 02/12/2021","study_txt":" Completion: 02/12/2021","study_completion_date":" 02/12/2021","last_update_posted":"2022-04-22"},{"id":"205cd8dd-a7f0-4f56-8d9f-9bea73d31597","acronym":"","url":"https://clinicaltrials.gov/study/NCT03283202","created_at":"2021-01-18T16:13:06.990Z","updated_at":"2024-07-02T16:36:30.991Z","phase":"Phase 1/2","brief_title":"Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors","source_id_and_acronym":"NCT03283202","lead_sponsor":"Celgene","biomarkers":" CD20","pipe":" | ","alterations":" LDH elevation","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • avadomide (CC-122) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 10/04/2017","start_date":" 10/04/2017","primary_txt":" Primary completion: 07/30/2019","primary_completion_date":" 07/30/2019","study_txt":" Completion: 12/16/2020","study_completion_date":" 12/16/2020","last_update_posted":"2021-04-29"},{"id":"7a037d36-03d3-48cf-8767-d5c6480ca38d","acronym":"Bio-CHIC","url":"https://clinicaltrials.gov/study/NCT03293173","created_at":"2021-01-18T16:16:10.577Z","updated_at":"2024-07-02T16:36:49.257Z","phase":"Phase 2","brief_title":"Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis","source_id_and_acronym":"NCT03293173 - Bio-CHIC","lead_sponsor":"Nordic Lymphoma Group","biomarkers":" ALK • MYC • BCL2 • CD20","pipe":" | ","alterations":" ALK positive • LDH elevation","tags":["ALK • MYC • BCL2 • CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/04/2017","start_date":" 08/04/2017","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2020-03-04"},{"id":"84a04cf0-e252-4987-a4ce-7095582ae74e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01325194","created_at":"2021-01-18T05:23:48.487Z","updated_at":"2024-07-02T16:36:49.334Z","phase":"Phase 2","brief_title":"CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis","source_id_and_acronym":"NCT01325194","lead_sponsor":"Nordic Lymphoma Group","biomarkers":" CD20","pipe":" | ","alterations":" LDH elevation","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Depocyte (liposomal cytarabine)"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 12/31/2019","study_completion_date":" 12/31/2019","last_update_posted":"2020-03-03"},{"id":"3353a8af-1e9c-4d8e-9a60-806a6600194a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00003402","created_at":"2021-01-17T22:51:16.471Z","updated_at":"2024-07-02T16:36:54.490Z","phase":"Phase 2","brief_title":"Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT00003402","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" CD34","pipe":" | ","alterations":" LDH elevation","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • cyclophosphamide • etoposide IV • carmustine • melphalan"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 01/01/1999","start_date":" 01/01/1999","primary_txt":" Primary completion: 12/01/2002","primary_completion_date":" 12/01/2002","study_txt":" Completion: 12/01/2002","study_completion_date":" 12/01/2002","last_update_posted":"2019-10-17"},{"id":"e6b452f7-3d85-4d39-99c3-3e76b049eaa2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01493479","created_at":"2021-01-18T06:15:18.779Z","updated_at":"2025-02-25T17:19:41.803Z","phase":"Phase 2","brief_title":"Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma","source_id_and_acronym":"NCT01493479","lead_sponsor":"The Christie NHS Foundation Trust","biomarkers":" CD20","pipe":" | ","alterations":" LDH elevation","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 06/06/2007","start_date":" 06/06/2007","primary_txt":" Primary completion: 01/01/2011","primary_completion_date":" 01/01/2011","study_txt":" Completion: 11/06/2015","study_completion_date":" 11/06/2015","last_update_posted":"2019-10-15"},{"id":"732deecc-9750-4040-802f-dbda2976c669","acronym":"","url":"https://clinicaltrials.gov/study/NCT00223899","created_at":"2021-01-18T00:45:34.790Z","updated_at":"2024-07-02T16:37:02.380Z","phase":"Phase 1","brief_title":"A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma","source_id_and_acronym":"NCT00223899","lead_sponsor":"Vical","biomarkers":" IL2","pipe":" | ","alterations":" LDH elevation","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 07/01/2005","start_date":" 07/01/2005","primary_txt":" Primary completion: 06/01/2008","primary_completion_date":" 06/01/2008","study_txt":" Completion: 10/01/2008","study_completion_date":" 10/01/2008","last_update_posted":"2019-02-27"},{"id":"0d8280ee-3f9d-43d2-b5a1-96d50ca39b3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00005089","created_at":"2021-01-17T22:57:10.158Z","updated_at":"2024-07-02T16:37:26.515Z","phase":"Phase 2","brief_title":"S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00005089","lead_sponsor":"Southwest Oncology Group","biomarkers":" CD20","pipe":" | ","alterations":" LDH elevation • CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone"],"overall_status":"Completed","enrollment":" Enrollment 71","initiation":"Initiation: 04/01/2000","start_date":" 04/01/2000","primary_txt":" Primary completion: 11/01/2004","primary_completion_date":" 11/01/2004","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2017-01-16"},{"id":"4e713caf-c33e-490a-9bd7-4cefcf1d9670","acronym":"","url":"https://clinicaltrials.gov/study/NCT01718691","created_at":"2021-01-18T07:29:45.697Z","updated_at":"2024-07-02T16:37:32.493Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma","source_id_and_acronym":"NCT01718691","lead_sponsor":"SymBio Pharmaceuticals","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive • LDH elevation","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 11/01/2011","start_date":" 11/01/2011","primary_txt":" Primary completion: 11/01/2013","primary_completion_date":" 11/01/2013","study_txt":" Completion: 11/01/2013","study_completion_date":" 11/01/2013","last_update_posted":"2016-04-27"}]